Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma

Maria Ana Ghetie, Erika M. Podar, Brian E. Gordon, Panayotis Pantazis, Jonathan W. Uhr, Ellen S. Vitetta

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We describe the use of an immunotoxin (IT) cocktail (anti-CD22- and anti-CD19-ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi lymphoma in SCID mice (SCID/Daudi). In a previous report, we demonstrated that this regimen was curative when given the day following tumor cell inoculation. Here, we show that combination therapy in mice with advanced tumor significantly increased their survival, although it was not curative. Importantly, the outcome of therapy was dependent upon the temporal order in which IT and chemotherapy were administered. Thus, the best anti-tumor effect was achieved when an IT cocktail was given before or at the same time as chemotherapy. When the IT was given after chemotherapy, there was no additional therapeutic benefit. Our results confirm the rationale of using combination therapy in the treatment of advanced B-cell neoplasia and suggest that ITs should be administered prior to or during chemotherapy.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalInternational Journal of Cancer
Volume68
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Immunotoxins
SCID Mice
Lymphoma
Drug Therapy
Neoplasms
Therapeutics
Ricin
Camptothecin
Doxorubicin
Cyclophosphamide
B-Lymphocytes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. / Ghetie, Maria Ana; Podar, Erika M.; Gordon, Brian E.; Pantazis, Panayotis; Uhr, Jonathan W.; Vitetta, Ellen S.

In: International Journal of Cancer, Vol. 68, No. 1, 1996, p. 93-96.

Research output: Contribution to journalArticle

Ghetie, Maria Ana ; Podar, Erika M. ; Gordon, Brian E. ; Pantazis, Panayotis ; Uhr, Jonathan W. ; Vitetta, Ellen S. / Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. In: International Journal of Cancer. 1996 ; Vol. 68, No. 1. pp. 93-96.
@article{e90635a71a6e4ee59246ede1add1ad16,
title = "Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma",
abstract = "We describe the use of an immunotoxin (IT) cocktail (anti-CD22- and anti-CD19-ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi lymphoma in SCID mice (SCID/Daudi). In a previous report, we demonstrated that this regimen was curative when given the day following tumor cell inoculation. Here, we show that combination therapy in mice with advanced tumor significantly increased their survival, although it was not curative. Importantly, the outcome of therapy was dependent upon the temporal order in which IT and chemotherapy were administered. Thus, the best anti-tumor effect was achieved when an IT cocktail was given before or at the same time as chemotherapy. When the IT was given after chemotherapy, there was no additional therapeutic benefit. Our results confirm the rationale of using combination therapy in the treatment of advanced B-cell neoplasia and suggest that ITs should be administered prior to or during chemotherapy.",
author = "Ghetie, {Maria Ana} and Podar, {Erika M.} and Gordon, {Brian E.} and Panayotis Pantazis and Uhr, {Jonathan W.} and Vitetta, {Ellen S.}",
year = "1996",
doi = "10.1002/(SICI)1097-0215(19960927)68:1<93::AID-IJC16>3.0.CO;2-7",
language = "English (US)",
volume = "68",
pages = "93--96",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma

AU - Ghetie, Maria Ana

AU - Podar, Erika M.

AU - Gordon, Brian E.

AU - Pantazis, Panayotis

AU - Uhr, Jonathan W.

AU - Vitetta, Ellen S.

PY - 1996

Y1 - 1996

N2 - We describe the use of an immunotoxin (IT) cocktail (anti-CD22- and anti-CD19-ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi lymphoma in SCID mice (SCID/Daudi). In a previous report, we demonstrated that this regimen was curative when given the day following tumor cell inoculation. Here, we show that combination therapy in mice with advanced tumor significantly increased their survival, although it was not curative. Importantly, the outcome of therapy was dependent upon the temporal order in which IT and chemotherapy were administered. Thus, the best anti-tumor effect was achieved when an IT cocktail was given before or at the same time as chemotherapy. When the IT was given after chemotherapy, there was no additional therapeutic benefit. Our results confirm the rationale of using combination therapy in the treatment of advanced B-cell neoplasia and suggest that ITs should be administered prior to or during chemotherapy.

AB - We describe the use of an immunotoxin (IT) cocktail (anti-CD22- and anti-CD19-ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi lymphoma in SCID mice (SCID/Daudi). In a previous report, we demonstrated that this regimen was curative when given the day following tumor cell inoculation. Here, we show that combination therapy in mice with advanced tumor significantly increased their survival, although it was not curative. Importantly, the outcome of therapy was dependent upon the temporal order in which IT and chemotherapy were administered. Thus, the best anti-tumor effect was achieved when an IT cocktail was given before or at the same time as chemotherapy. When the IT was given after chemotherapy, there was no additional therapeutic benefit. Our results confirm the rationale of using combination therapy in the treatment of advanced B-cell neoplasia and suggest that ITs should be administered prior to or during chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029982902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029982902&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960927)68:1<93::AID-IJC16>3.0.CO;2-7

DO - 10.1002/(SICI)1097-0215(19960927)68:1<93::AID-IJC16>3.0.CO;2-7

M3 - Article

C2 - 8895546

AN - SCOPUS:0029982902

VL - 68

SP - 93

EP - 96

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -